



# Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

The General Manager  
Corporate Relationship Department  
**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai -400 001

Date: 30.10.2021

Ref: ZENLABS ETHICA LIMITED (SECURITY CODE NO.: 530697)

Sub.: Approval of Un-audited Financial Results of the company for the quarter ended 30<sup>th</sup> September, 2021.

Respected Madam/Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today on Saturday the 30<sup>th</sup> day of October, 2021 at 2:00 p.m. at the registered office of the company at Plot No. 194-195, 3<sup>rd</sup> Floor, Industrial Area, Phase-II, Chandigarh-160002 have considered and approved the un-audited financial results for the quarter and half year ended on September 30, 2021 as per Regulation 33 of SEBI (LODR), 2015. In this regard, we are enclosing herewith:

1. Un-audited Financial Results of the company for the quarter and half year ended on September 30, 2021 ;
2. Limited Review Report for the period ended on 30th September, 2021.

You are requested to kindly take the same on record.

Please also note that the company has made necessary arrangement for the publication of Un-audited Financial results as per the requirement of the SEBI (LODR) Regulations, 2015.

Thanking You

Yours Truly,  
For **Zenlabs Ethica Limited**

**SANJAY DHIR**  
Wholetime Director  
DIN: 02452461







# Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

## PART I: STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2021

Sr. No	Particulars	(₹ in Lakhs except EPS data)					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2021 (Unaudited)	30-06-2021 (Unaudited)	30-09-2020 (Unaudited)	30-09-2021 (Unaudited)	30-09-2020 (Unaudited)	31-03-2021 Audited
1	Revenue from Operations	1,833.19	1,890.36	1,503.80	3,723.55	2,799.85	5,664.02
2	Other Income	3.63	2.06	2.11	5.69	7.18	12.41
3	<b>Total Income (1+2)</b>	<b>1,836.82</b>	<b>1,892.42</b>	<b>1,505.90</b>	<b>3,729.24</b>	<b>2,807.03</b>	<b>5,676.42</b>
4	Expenditure						
	a) Purchase of stock in trade	1,604.40	1,532.12	1,046.09	3,136.52	2,360.27	4,730.77
	b) (Increase)/decrease in stock-in-trade	(143.15)	22.47	220.87	(120.68)	17.79	(57.99)
	c) Employees benefit expenses	76.25	65.60	85.95	141.85	159.36	335.41
	d) Finance costs	2.16	0.81	1.05	2.97	1.78	3.73
	e) Depreciation & Amortisation	5.61	5.62	8.33	11.23	14.03	27.36
	f) Other Expenditure	251.32	225.54	123.96	476.86	224.10	544.70
	<b>Total Expenses</b>	<b>1,796.59</b>	<b>1,852.16</b>	<b>1,486.24</b>	<b>3,648.75</b>	<b>2,777.33</b>	<b>5,583.98</b>
5	<b>Profit before Exceptional &amp; Extraordinary Items (3-4)</b>	<b>40.23</b>	<b>40.26</b>	<b>19.66</b>	<b>80.49</b>	<b>29.71</b>	<b>92.44</b>
6	Exceptional Items	-	-	-	-	-	-
7	<b>Profit Before Tax (5-6)</b>	<b>40.23</b>	<b>40.26</b>	<b>19.66</b>	<b>80.49</b>	<b>29.71</b>	<b>92.44</b>
8	Tax Expenses						
	a) Current Tax	2.50	10.06	-	12.56	-	9.26
	b) MAT Credit entitlement	(4.29)	-	-	(4.29)	-	-
	c) Deferred Tax	16.94	-	-	16.94	-	-
9	<b>Profit(+)/ Loss(-) for the period (7-8)</b>	<b>25.08</b>	<b>30.20</b>	<b>19.66</b>	<b>55.28</b>	<b>29.71</b>	<b>83.19</b>
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Re-measurement of the net defined benefit plans	(1.59)	0.05	9.87	(1.54)	9.87	8.85
	Tax on above	0.40	-	-	0.40	-	-
11	<b>Total Other comprehensive Income, net of tax</b>	<b>(1.19)</b>	<b>0.05</b>	<b>9.87</b>	<b>(1.14)</b>	<b>9.87</b>	<b>8.85</b>
12	<b>Total comprehensive Income, for the period</b>	<b>23.89</b>	<b>30.25</b>	<b>29.53</b>	<b>54.14</b>	<b>39.57</b>	<b>92.03</b>
13	<b>Paid up equity share capital</b> (Face Value of ₹ 10/- each per share)	<b>651.00</b>	<b>651.00</b>	<b>651.00</b>	<b>651.00</b>	<b>651.00</b>	<b>651.00</b>
14	<b>Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items</b>						
	-Basic	0.39	0.46	0.45	0.85	0.61	1.41
	-Diluted	0.39	0.46	0.45	0.85	0.61	1.41

### NOTES :

- The above financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 30<sup>th</sup> October, 2021. The statutory auditors of the Company have conducted a limited review of the unaudited financial results and have expressed an unmodified review opinion on these financial results.
- The Standalone financial results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The Company is considered to be a single segment company engaged in the trading of pharmaceuticals formulation. Consequently, the Company has, in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 "Operating Segment".
- The Company has considered the possible impact of pandemic relating to Novel Corona Virus (COVID-19) on its financial results/position using the internal and external sources of information available up to the date of approval of these financial results and expects to recover the carrying value of its assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial results, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial results may differ from that estimated as at the date of approval of these financial results.
- Previous period figures have been re-grouped/ re-classified, wherever necessary, to conform to current period's classifications in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1<sup>st</sup> April, 2021.

Place: Chandigarh  
Date: 30<sup>th</sup> October, 2021



By order of Board  
For Zenlabs Ethica Limited

*Sanjay Dhir*  
Sanjay Dhir  
DIN 02452461

Whole Time Director cum Chief Financial Officer





# Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

## Statement of Assets and Laibilities as at 30<sup>th</sup> September, 2021

Particulars	□ in Lakhs	
	As at 30 <sup>th</sup> September, 2021 (Unaudited)	As at 31 <sup>st</sup> March, 2021 (Audited)
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment		
Financial assets	127.69	138.79
Investments		
Other financial assets	70.20	70.20
Deferred tax assets (Net)	148.16	-
	17.59	34.53
<b>Total non-current Assets</b>	<b>363.64</b>	<b>243.51</b>
<b>Current assets</b>		
Inventories		
Financial assets	639.17	518.49
Trade receivables		
Cash and cash equivalents	2,419.28	1,887.96
Bank balances other than cash and cash equivalents	1.70	153.39
Other financial assets	28.32	12.64
Other current assets	9.19	5.60
	427.72	389.48
<b>Total current Assets</b>	<b>3,525.38</b>	<b>2,967.55</b>
<b>Total Assets</b>	<b>3,889.02</b>	<b>3,211.07</b>
<b>Equity and Liabilities</b>		
<b>Equity</b>		
Equity share capital	651.00	651.00
Other equity	245.05	190.90
<b>Total equity</b>	<b>896.05</b>	<b>841.90</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	20.28	23.41
Lease liabilities	200.81	161.58
Provisions	32.69	28.82
<b>Total non-current liabilities</b>	<b>253.78</b>	<b>213.81</b>
<b>Current liabilities</b>		
Financial liabilities		
Borrowings	10.04	14.29
Lease liabilities	81.22	60.60
Trade payables		
Total outstanding dues of micro enterprises and sma	1,873.59	554.83
Total outstanding dues of creditors other than		
micro enterprises and small enterprises	568.39	1,368.86
Other financial liabilities	89.08	43.29
Other current liabilities	107.72	110.32
Provisions	3.55	3.17
Current tax liabilities [Net]	5.60	-
<b>Total current liabilities</b>	<b>2,733.59</b>	<b>2,155.36</b>
<b>Total equity and liabilities</b>	<b>3,889.02</b>	<b>3,211.07</b>

Place: Chandigarh  
Date: 30<sup>th</sup> October, 2021



By order of Board  
For Zenlabs Ethica Limited

*Sanjay Dhir*  
Sanjay Dhir  
DIN 02452461

Whole Time Director cum Chief Financial Officer





# Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

## Cash Flow Statement for the half year ended 30<sup>th</sup> September, 2021

□ in Lakhs		
Particulars	For the half year ended 30 <sup>th</sup> September, 2021	For the half year ended 30 <sup>th</sup> September, 2020
<b>A. Cash Flow from Operating Activities</b>		
Profit before taxation	80.49	29.71
Adjustments for:		
Depreciation	11.23	14.03
MAT credit entitlement	-	-
Interest expense	2.97	1.78
Interest income	(5.69)	(5.54)
Loss on sale of property, plant and equipment	-	1.26
Adjustment to equity	-	0.00
<b>Operating profit before working capital changes</b>	<b>89.00</b>	<b>41.24</b>
Adjustments for changes in working capital :		
(Increase)/Decrease in non-current assets and current assets	(857.68)	165.01
(Increase)/Decrease in non-current liabilities and current liabilities	649.79	(229.95)
(Increase)/Decrease in inventories	-	-
Increase/(Decrease) in trade and other payables	-	-
Increase/(Decrease) in Long term Liabilities	-	-
<b>Net cash generated from operating activities</b>	<b>(118.89)</b>	<b>(23.70)</b>
<b>B. Cash flow from investing activities:</b>		
Purchase of fixed assets and capital work in progress	(0.13)	(42.83)
Sale Proceeds from fixed assets	-	6.00
Interest received	5.69	5.54
<b>Net cash used in investing activities</b>	<b>5.56</b>	<b>(31.29)</b>
<b>C. Cash flow from financing activities:</b>		
Proceeds/(Repayments) from/ to long term borrowings	(7.38)	17.56
Payment of lease liabilities	(28.01)	-
Interest paid	(2.97)	(1.78)
<b>Net cash generated/(used) in financing activities</b>	<b>(38.36)</b>	<b>15.78</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(151.69)</b>	<b>(39.21)</b>
Cash and cash equivalents at the beginning of the year	153.39	209.30
Cash and cash equivalents at the end of the year	1.70	170.09

Place: Chandigarh  
Date: 30<sup>th</sup> October, 2021



By order of Board  
For Zenlabs Ethica Limited

*Sanjay Dhir*

Sanjay Dhir  
DIN 02452461

Whole Time Director cum Chief Financial Officer

**Independent Auditor's Review Report on Unaudited Quarterly and Year to date Financial Results of Zenlabs Ethica Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).**

**To**

**The Board of Directors**  
**Zenlabs Ethica Limited**

1. We have reviewed the accompanying statement of unaudited financial results ("the statement") of **Zenlabs Ethica Limited** ("the Company") for the quarter ended 30<sup>th</sup> September, 2021 and the year to date results for the period 1<sup>st</sup> April, 2020 to 30<sup>th</sup> September, 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in an Audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains

any material misstatement.

5. The comparative financial information of the Company for the quarter ending 30<sup>th</sup> June, 2021, for the quarter and the half year ended 30<sup>th</sup> September, 2020 and for the year ended 31<sup>st</sup> March, 2021 prepared in accordance with Ind AS included in the statement was reviewed/ audited by the predecessor auditor vide their unmodified reports dated 22<sup>nd</sup> July, 2021, 10<sup>th</sup> November, 2020, and 26<sup>th</sup> May, 2021 respectively, whose report have been furnished to us by the management and which have been relied upon for the purpose of our review of the statement. Our review report is not modified in respect of this matter.

*for* **N Kumar Chhabra and Co.**

Chartered Accountants

Firm registration Number 00837N

**ASHISH**

**CHHABRA**

Digitally signed by  
ASHISH CHHABRA  
Date: 2021.10.30 14:03:04  
+05'30'

**CA. Ashish Chhabra**

*Partner*

Membership Number 507083

**Place:** Chandigarh

**Date:** 30<sup>th</sup> October, 2021

**UDIN:** 21507083AAAAEY3537